We identified 28 PSMs from five cancer types in which KRAS G12D somatic mutation is frequently reported (Fig. 2a, Supplementary Data 2), and a representative MS/MS spectrum identifying the mutant peptide in a pancreatic cancer sample is shown in Fig. 2b. This evidence concerns the gene KRAS and pancreatic neoplasm.